芬特明/托吡酯治疗肥胖糖尿病尿酸结石患者的开放标签随机可行性试验
这项开放标签随机可行性试验纳入肥胖、糖尿病、尿pH<5.8且结石成分≥80%尿酸的患者,按2:1随机接受芬特明18.75mg/托吡酯100mg或常规对照,主要终点为CT结石体积变化。
要点
- 芬特明/托吡酯在肥胖糖尿病尿酸结石患者中耐受良好,无严重不良事件。
- 干预组体重下降、尿pH升高、HbA1c和尿枸橼酸降低。
核心结论
- 在肥胖合并糖尿病及尿酸结石患者中,芬特明/托吡酯耐受良好,符合方案分析显示结石负荷显著减少。
研究设计与样本
- 18个月前瞻性开放标签随机可行性试验,按2:1区组随机分配至芬特明18.75mg/托吡酯100mg组或常规对照组,并进行剂量递增。
- 15例完成研究,服药依从性73%,无严重不良事件。
主要发现
- 研究结束时与对照组均值比较,干预组体重变化为-10.2 vs +2.9 kg,HbA1c变化为-0.2 vs +0.5。
- 干预组24小时尿枸橼酸为309±81 vs 951±782 mg,尿酸过饱和度为0.7±1.1 vs 1.8±1.0。
临床怎么用
- 对于肥胖合并糖尿病的尿酸结石患者,芬特明/托吡酯可作为探索性治疗选择,但需注意该研究为可行性试验。
- 治疗期间应监测体重、HbA1c、尿pH、尿枸橼酸及尿酸过饱和度等指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to determine whether medical treatment of obesity, diabetes, and low urine pH with combination phentermine/topiramate affects uric acid (UA) kidney stone burden. MATERIALS AND METHODS: Participants with obesity, diabetes mellitus, normal renal function, urine pH < 5.8, and stone analysis ≥ 80% UA were block randomized (2:1 ratio) to phentermine 18.75 mg/topiramate 100 mg vs pragmatic controls for an 18-month, prospective, open-label feasibility study with dose escalation. The primary outcome was change in CT stone volume. Secondary outcomes included medication adherence; patient safety; and change in anthropometrics, laboratory studies, and body composition. RESULTS: Nineteen participants (age 62.1 ± 9.8 years; 68% male; mean BMI = 36.3 ± 2.9 kg/m2) were randomized, and 15 completed the study with 73% pill adherence and no serious adverse events. Stone volume by intention-to-treat analysis fell by 52% in the intervention group and rose by 8.6% in the control group (P = .10), with per-protocol analysis demonstrating statistically significant stone volume reduction (P = .02). At study end and compared with means of controls, the intervention group had greater weight loss (-10.2 vs +2.9 kg), reduction in hemoglobin A1c levels (-0.2 vs +0.5), lower 24-hour urine citrate (309 ± 81 vs 951 ± 782 mg), and lower UA supersaturation (0.7 ± 1.1 vs 1.8 ± 1.0), along with higher 24-hour urine pH (6.2 ± 0.5 vs 5.5 ± 0.4) and calcium phosphate supersaturation (0.9 ± 0.8 vs 0.2 ± 0.1; all P < .05). CONCLUSIONS: Among obese participants with diabetes mellitus and UA nephrolithiasis, phentermine/topiramate was well tolerated and demonstrated significant stone burden reductions by per-protocol analysis. The intervention group also had greater weight loss, higher urinary pH, and lower hemoglobin A1c and urinary citrate levels. These data provide a framework to study the impact of this novel alternative UA therapy on a wider range of patients with obesity and diabetes.
引用
- Canales BK, Heiman J, Terry R, et al. Phentermine/Topiramate in Obese, Diabetic Uric Acid Stone Formers: An Open-Label Randomized Feasibility Trial. J Urol. 2026. PMID: 42361212. doi:10.1097/JU.0000000000005189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。